fashion -WSS

fashion

author：entertainment 2025-09-29 12:55:00 - browse：84763

Lung cancer under microscope — coverage from STAT — Lung cancer Adobe

CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen for lung cancer, published a scientific paper on Monday describing key aspects of the test and unveiled the design of a key clinical trial.

Delfi also announced that the Merck Global Health Innovation Fund, the VC arm of the drug giant, has made an investment of an undisclosed amount in the company.

Unlike Grail, a unit of Illumina, or Exact Sciences, which seeks to develop a blood test that can be used to screen for multiple types of cancer, Delfi is focusing on a single disease — lung cancer — in which the utility of screening with existing technology is not in dispute. Using low-dose CT scans to detect lung cancer is considered an established technology for people at higher risk of lung cancer. However, far too few people get screened.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： State of the Union pitch: Bigger Medicare drug price negotiations

WSS

Ozempic has benefits for kidney disease as well as diabetes

U.K. considers world's first use of meningitis vaccine to address gonorrhea

IVF doctors demand details after CooperSurgical lawsuit

Pregnant women don't need prenatal multivitamins, study concludes

Fetal cell organoids grown from amniotic fluid, study finds

Readout LOUD podcast: A CRISPR milestone, biotech mixology

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Peter Hotez and the public health issue of online harassment

Does good food count as health care? Study aims to find out

ChatGPT in medicine: STAT answers readers' burning questions

Childhood cancer progress stalls for Black, Hispanic kids: Report

State Dept. review finds Biden bears some blame for Afghanistan failures

Weight loss drug costs may need more research, senator suggests

Duchenne breakthrough therapy leaves behind pioneering families

Harvard's David Sinclair gets blowback over aging

Dobbs anniversary: the lost opportunity of abortion as health care

World's first CRISPR

entertainment

Longer MASH drug regimen improved liver, Akero study finds

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

CRISPR pioneers react to Casgevy, first gene

Ransomware attacks on hospitals: Study outlines patient impact

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Florida health officials providing scant details on measles cases

leisure time

hotspot

knowledge

focus